Navigation Links
Denosumab Demonstrates Superiority Over Zometa(R) in Delay of Complications Due to Bone Metastases in Advanced Breast Cancer Patients
Date:9/22/2009

perior to Zometa with respect to the first, on-study SRE, as well as the first-and-subsequent on-study SREs, and to assess the safety and tolerability of denosumab compared with Zometa.

About Denosumab and Amgen's Research in Bone Biology

Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, the essential regulator of osteoclasts (the cells that break down bone). With more than 19,000 patients in trials across indications worldwide, the denosumab development program is the largest ever initiated by Amgen. This broad and deep development program demonstrates Amgen's commitment to researching and delivering pioneering medicines to patients with unmet medical needs. Amgen is studying denosumab in numerous tumor types across the spectrum of cancer-induced bone disease. Over 11,000 patients have been enrolled in the denosumab oncology clinical trials, testing the drug for the reduction of SREs in breast cancer patients, for the amelioration of treatment-induced bone loss in patients with breast or prostate cancers, for the prevention of SREs due to the spread of cancer to the bone in patients with multiple myeloma or those suffering from a variety of solid tumors, and for its potential to delay bone metastases in prostate cancer.

Bone Metastases: Impact and Prevalence

Bone metastases, cancer cells that separate from tumors and migrate to bone tissue where they settle and grow, occur in more than 1.5 million people worldwide.(2) With improvements in cancer care, including earlier diagnosis and new treatment options, leading to increases in survival rates(3), the number of patients developing metastatic disease secondary to a primary cancer is increasing. Bone metastases are a significant problem for patients with certain types of advanced cancer, with incidence rates of nearly 100 percent in myeloma patients and as high as 75 per
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
2. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
3. ER Doctor Demonstrates Breast Pump on Live TV with Patented New Freemie Hands-Free System
4. NexBio(R) Demonstrates DAS181 (Fludase(R)*), a Broad-Spectrum Drug Candidate, Inhibits Influenza Viral Infection in Human Lung Tissue
5. Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals Lead Antibody
6. Abbott HIV Test Demonstrates Earlier Disease Detection
7. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
8. New Pre-Clinical Data on OmniGuides BeamPath NEURO(TM) Demonstrates Precise Cutting in Brain Tissue
9. Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia
10. PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer
11. NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 /PRNewswire-iReach/ -- A case study from ... the school,s bioengineering department and the Intel® Internet ... Software Academic Program, UCSD,s research focuses on exploring ... body.  Photo - http://photos.prnewswire.com/prnh/20140819/137540 ... work of Dr. Todd P. Coleman , ...
(Date:8/19/2014)... Shimadzu Scientific Instruments has introduced ... Nexera-i, adding to the company’s extensive line-up of ... intuitive operating environment, and full automation, the i-Series ... for conventional to ultra-high-speed analysis. , ... design so users can begin building the lab ...
(Date:8/19/2014)... CA (PRWEB) August 19, 2014 Robin ... Parkinson’s disease can take on an individual. Symptoms ... decreased facial expression, problems swallowing and severe depression. ... the dying off of dopamine producing neurons of the ... from a disease that slowly and progressively gets worse, ...
(Date:8/19/2014)... 19, 2014   Synthetic Biologics, Inc. ... anti-infective biologic and drug programs targeting specific pathogens ... that its novel C. difficile development ... Interscience Conference on Antimicrobial Agents and Chemotherapy ... Synthetic Biologics, Senior Vice ...
Breaking Biology Technology:Intel and University of San Diego Bioengineering Department Release Case Study on Health Sciences Research 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 2As We Mourn Robin Williams’ Passing, His Death Sheds Light on Patients Struggling with Parkinson’s Disease 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 2Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 3Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC 4
... colon, and ... prostate cancers-, TORONTO, Oct. ... and developing the next wave of,antibody therapeutics, today announced that the ... completed its first,toxicology study and has shown good efficacy in animal ...
... Wrong Should be put ... Stefano, ROME, October 23 Giovanni Di Stefano has called ... In,a letter supported by Dr John Trestrail who researched the flawed,conviction ... for,the pardon to be ,effective forthwith notwithstanding the passage of time.,Other ...
... ON, Oct. 22 /PRNewswire-FirstCall/ - YM BioSciences Inc.,(AMEX: ... oncology company that identifies,develops and commercializes differentiated products ... Directors has adopted a renewed,Shareholder Rights Plan Agreement. ... treatment of shareholders in connection with any take-over ...
Cached Biology Technology:ARIUS announces cancer stem cell antibody program successfully completes first toxicology study 2ARIUS announces cancer stem cell antibody program successfully completes first toxicology study 3YM Biosciences announces adoption of renewed Shareholders' Rights Plan 2YM Biosciences announces adoption of renewed Shareholders' Rights Plan 3
(Date:8/20/2014)... of sunscreen and seawater signals a relaxing trip to ... idyllic beach vacation comes with an environmental hitch. When ... sea, they can become toxic to some of the ... many other marine animals. Their study appears in the ... Antonio Tovar-Sanchez and David Snchez-Quiles point out that other ...
(Date:8/20/2014)... bags could one day be made out of cocoa, ... now reporting. The novel process they developed and their ... agricultural and plastic waste problems, appear in the ACS ... Bayer and colleagues at the Italian Institute of Technology ... 2012, its production reached 288 million tons worldwide, but ...
(Date:8/20/2014)... to about 4,000 members, it triggers an important first ... special type of comb used for rearing male reproductive, ... of Neurobiology and Behaviour at Cornell University, led by ... honeybee colonies. The results are published in Springer,s journal ... , Reproduction isn,t always a honeybee colony,s top priority. ...
Breaking Biology News(10 mins):Worker bees 'know' when to invest in their reproductive future 2
... time, researchers at the UCLA Henry Samueli School of ... its limits by genetically modifying Escherichia coli , ... unusually long-chain alcohols essential in the creation of biofuels. ... synthesize long-chain alcohols containing five carbon atoms," said James ...
... your time among stores, restaurants and skyscrapers, it may be ... A new study in Psychological Science , a journal ... in nature may be more beneficial for mental processes than ... Jonides, and Stephen Kaplan from the University of Michigan designed ...
... and make way for a "green" holiday. Here are ... environmentally friendly, courtesy of the American Chemical Society (ACS), ... Chemistry Institute. The Institute works to foster the discovery ... generation and use of hazardous substances. ,To reduce your ...
Cached Biology News:Researchers push nature beyond its limits to create higher-density biofuels 2
Mouse polyclonal antibody to PRDM2 - PR domain containing 2, with ZNF domain...
Anti Human S14G-Humanin Polyclonal Antibody...
... familiar interface for data capture, recording, ... transition from paper to this powerful ... contains an integrated LIMS, notary service, ... These functions allow LABTrack to achieve ...
High voltage electrophoresis power supply...
Biology Products: